

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

TEVA PHARMACEUTICALS USA, INC.,  
Petitioner,

v.

CORCEPT THERAPEUTICS, INC.  
Patent Owner.

---

PGR2019-00048  
Patent 10,195,214 B2

---

**PETITIONER'S EXHIBIT LIST**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

<i>Teva</i> <i>Exhibit #</i>	<i>Description</i>
<b>1001</b>	Belanoff, J.K., "Concomitant Administration Of Glucocorticoid Receptor Modulators And CYP3A Inhibitors," U.S. Patent No. 10,195,214 B2 (filed June 19, 2017; issued February 5, 2019)
<b>1002</b>	Declaration of David J. Greenblatt, M.D.
<b>1003</b>	Curriculum Vitae for David J. Greenblatt, M.D.
<b>1004</b>	Korlym Label (2012)
<b>1005</b>	Lee <i>et al.</i> , Office of Clinical Pharmacology Review NDA 20687 (Addendum, Korlym™, Mifepristone) (2012)
<b>1006</b>	FDA Approval Letter for Korlym (mifepristone) tablets, NDA 20217, dated February 17, 2012
<b>1007</b>	Tsunoda, S.M., <i>et al.</i> , "Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole," <i>Clin. Pharmacol. Ther.</i> 66(5): 461–471 (1999)
<b>1008</b>	Ullmann, A., <i>et al.</i> , "Method For Treating Cushing's Syndrome," U.S. Patent Application Publication No. 2010/0261693 A1 (filed October 13, 2008; published October 14, 2010)
<b>1009</b>	Sartor, O. and Cutler, G.B., "Mifepristone: Treatment of Cushing's Syndrome," <i>Clinical Obstetrics and Gynecology</i> 39(2): 506–510 (1996)
<b>1010</b>	Pozza, C., <i>et al.</i> , "Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics," <i>J. Oncol.</i> 109: 1–9 (2012)
<b>1011</b>	Castinetti, F., "Medical Treatment of Cushing's Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone," <i>Neuroendocrinology</i> 92(suppl. 1): 125–130 (2010)
<b>1012</b>	Nieman, L.K., "Successful Treatment of Cushing's Syndrome with the Glucocorticoid Antagonist RU 486*," <i>J. Clin. Endocrinol. Metab.</i> 61(3): 536–540 (1985)

<i>Teva</i> <i>Exhibit #</i>	<i>Description</i>
<b>1013</b>	Brogden, R.N., <i>et al.</i> , "Mifepristone A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential," <i>Drugs</i> 45(3): 384–409 (1993)
<b>1014</b>	Molitch, M.E., "Current approaches to the pharmacological management of Cushing's disease," <i>Mol. Cell. Endocrinol.</i> 408: 185–189 (2015)
<b>1015</b>	Sitruk-Ware, R. and Spitz, I.M., "Pharmacological properties of mifepristone: toxicology and safety in animal and human studies," <i>Contraception</i> 68: 409–420 (2003)
<b>1016</b>	Heikinheimo, O., "Pharmacokinetics of The Antiprogestone RU 486 in Women During Multiple Dose Administration," <i>J. Steriod. Biochem.</i> 32(1A): 21–25 (1989)
<b>1017</b>	Heikinheimo, O., <i>et al.</i> , "The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action," <i>Contraception</i> 68: 421–426 (2003)
<b>1018</b>	Blasey, C.M., <i>et al.</i> , "Efficacy and Safety of Mifepristone for the Treatment of Psychotic Depression," <i>J. Clin. Psychopharmacol.</i> 31:436–440 (2011)
<b>1019</b>	Belanoff, J.K., "Optimizing Mifepristone Levels in Plasma Serum of Patients Suffering from Mental Disorders Treatable with Glucocorticoid Receptor Antagonists," U.S. Patent No. 8,921,348 B2 (filed October 29, 2013; issued December 30, 2014)
<b>1020</b>	Belanoff, J.K., "Optimizing Mifepristone Levels in Plasma Serum of Patients Suffering from Mental Disorders Treatable with Glucocorticod Receptor Antagonists," U.S. Patent No. 8,598,149 B2 (filed August 27, 2008; issued December 3, 2013)
<b>1021</b>	Castinetti, F., <i>et al.</i> , "Merits and pitfalls of mifepristone in Cushing's syndrome," <i>Eur. J. Endocrinol.</i> 160: 1003–1010 (2009)
<b>1022</b>	Jang, G.R., <i>et al.</i> , "Identification of CYP3A4 as the Principal Enzyme Catalyzing Mifepristone (RU 486) Oxidation in Human Liver Microsomes," <i>Biochem. Pharmacol.</i> 52: 753–761 (1996)

<b><i>Teva</i></b> <b><i>Exhibit #</i></b>	<b><i>Description</i></b>
<b>1023</b>	Greenblatt, D., “ <i>In Vitro</i> Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet,” <i>Clin. Pharm. Ther.</i> 95(2): 133–135 (2014)
<b>1024</b>	Greenblatt, D.J., <i>et al.</i> , “Mechanism of cytochrome P450-3A inhibition by ketoconazole,” <i>J. Pharm. Pharmacol.</i> 63: 214–221 (2011)
<b>1025</b>	Greenblatt, D.J. and von Moltke, L.L., “Clinical Studies of Drug-Drug Interactions: Design and Interpretation,” in <i>Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges</i> . Pang, K.S. <i>et al.</i> , ed., pp. 625–649, New York, Springer (2010)
<b>1026</b>	Greenblatt, D.J., <i>et al.</i> , “The CYP3 Family” in <i>Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and other Xenobiotics</i> . Ionnides, C., ed., pp. 354–383, Royal Society of Chemistry: (2008)
<b>1027</b>	Ohno, Y., <i>et al.</i> , “General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs,” <i>Clin. Pharmacokinet.</i> 46(8): 681–696 (2007)
<b>1028</b>	Archive History of NCT00936741 History of Changes for Study: NCT00936741 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome (July 9, 2009) on ClinicalTrials.gov
<b>1029</b>	Fleseriu, M., <i>et al.</i> , “Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing’s Syndrome,” <i>J. Clin. Endocrinol. Metab.</i> 97(6):2039–2049 (2012)
<b>1030</b>	Morgan, F.H. and Laufgraben, M.J., “Mifepristone for Management of Cushing’s Syndrome,” <i>Pharmacotherapy</i> 33(3):319–329 (2013)
<b>1031</b>	Schteingart, D.E., “Drugs in the medical treatment of Cushing's syndrome,” <i>Expert Opin. Emerging Drugs</i> 14(4):661–671 (2009)

<i>Teva</i> <i>Exhibit #</i>	<i>Description</i>
<b>1032</b>	Dang, C.N. and Trainor, P., “Pharmacological Management of Cushing’s Syndrome: An Update,” <i>Arq. Bras. Endocrinol. Metab.</i> 51(8):1339–1348 (2007)
<b>1033</b>	Zhang, L., <i>et al.</i> , “Predicting Drug–Drug Interactions: An FDA Perspective,” <i>The AAPS Journal</i> 11(2): 300–306 (2009)
<b>1034</b>	Nguyen, D. and Minze, S., “Effects of Ketoconazole on the Pharmacokinetics of Mifepristone, a Competitive Glucocorticoid Receptor Antagonist, in Healthy Men,” <i>Adv. Ther.</i> 34:2371–2385 (2017)
<b>1035</b>	File History of U.S. Patent No. 10,195,214 B2
<b>1036</b>	Korlym Label Revised: 05/2017 (2017)
<b>1037</b>	Kaesar, B., <i>et al.</i> , “Drug-Drug Interaction Study of Ketoconazole and Ritonavir-Boosted Saquinavir,” <i>Antimicrobial Agents and Chemotherapy</i> 53(2): 609–614 (2009)
<b>1038</b>	Truong, H.L., <i>et al.</i> , “Budget impact of pasireotide for the treatment of Cushing’s disease, a rare endocrine disorder associated with considerable comorbidities,” <i>J. Med. Economics</i> 17(4): 299–295 (2014)
<b>1039</b>	Belanoff, J. and Gross, C., “Optimizing Mifepristone Levels for Cushing's Patients,” U.S. Patent No. 9,943,526 B2 (filed April 20, 2016; issued April 17, 2018)
<b>1040</b>	“A Guide to Drug Safety Terms,” FDA Consumer Health Information / U. S. Food and Drug Administration, (2012) downloaded from <a href="http://www.tinyurl.com/y6oao2sj">www.tinyurl.com/y6oao2sj</a>
<b>1041</b>	“Guidance for Industry Drug Interaction Studies — Study Design, Data Analysis, and Implications for Dosing and Labeling,” U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2006)
<b>1042</b>	File History for U.S. Patent No. 9,943,526 B2

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.